Theratechnologies Inc (TH) Given New C$3.25 Price Target at National Bank Financial
Several other equities research analysts have also recently issued reports on the company. Canaccord Genuity decreased their price objective on Theratechnologies from C$4.25 to C$3.75 in a report on Thursday, July 7th. Mackie decreased their price objective on Theratechnologies from C$5.30 to C$4.40 in a report on Wednesday, July 6th.
Theratechnologies (TSE:TH) traded up 1.74% during trading on Thursday, reaching $2.92. The company’s stock had a trading volume of 11,508 shares. The company has a 50 day moving average price of $2.62 and a 200-day moving average price of $2.42. Theratechnologies has a 52 week low of $1.26 and a 52 week high of $3.74. The company has a market capitalization of $192.52 million and a PE ratio of 265.45.
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company’s product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Receive News & Stock Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related stocks with our FREE daily email newsletter.